Lack of an Association or an Inverse Association Between Low-Density Lipoprotein Cholesterol and Mortality in the Elderly

ByCrossFitJuly 21, 2020

Found in:200722,Essentials,Science

Question: Does elevated LDL cholesterol predict increased mortality among the elderly?

Takeaway: No, it does not. Across a variety of populations, increased LDL cholesterol either has no relationship with overall mortality or predicts decreased mortality risk among the elderly. Efforts to reduce LDL cholesterol among elderly populations may increase overall mortality rates.

In this 2016 review, a team including CrossFit Health contributors Uffe Ravnskov, David Diamond, Malcolm Kendrick, and Aseem Malhotra analyzes the associations between LDL cholesterol and cardiovascular as well as overall mortality within elderly populations.

LDL cholesterol is still widely believed to play a primary, causal role in heart disease, which is one of the leading causes of death among the elderly (1). Large cohort trials, however, have failed to find the association between cholesterol levels and mortality implied by this hypothesis (2); some trials, such as those in Japanese populations, have found an inverse association (3). A recent trial found an association between total cholesterol and cardiovascular mortality, but the strength of this association decreased substantially with increasing age (4). This is particularly interesting in light of the fact that the majority of cardiovascular burden is felt among the elderly.

To comprehensively assess the relationship between LDL cholesterol (LDL-C) and overall and cardiovascular mortality among the elderly, this team gathered 19 studies containing 30 cohorts and 68,095 total participants. The relationship between LDL cholesterol and total mortality could be calculated in 28 cohorts, and between LDL cholesterol and cardiovascular mortality in nine cohorts. The team’s findings are summarized in the table below:

Table 1: Summary of surveyed studies and their results

Fourteen of 28 cohorts showed a statistically significant inverse association between LDL-C and all-cause mortality. An additional two cohorts showed an inverse association that failed to reach statistical significance. One further cohort showed elevated all-cause mortality in individuals with the lowest cholesterol levels, without evidence of an overall trend. The remaining cohorts showed no association between LDL-C and all-cause mortality. No surveyed cohort showed a positive relationship between LDL-C and all-cause mortality — in other words, in no cohort did higher LDL-C indicate higher mortality risk.

In seven of nine cohorts, no statistically significant relationship was found between LDL-C and cardiovascular mortality. The two remaining cohorts showed a J-shaped and U-shaped relationship between LDL-C and cardiovascular mortality. In no cohort was there a significant positive relationship between LDL-C and cardiovascular mortality.

The authors note the magnitude of effect here is greater than that described in any statin trial — that is, the magnitude of mortality reduction between the second-lowest and lowest quartiles of cholesterol was generally greater than 10% and only increased in a dose-dependent relationship with further cholesterol elevation. In other words, even if all individuals with higher cholesterol had been taking statins, zero individuals with lower cholesterol had been taking statins, and the effect of statins on mortality was assessed using the most favorable data available, this still would fail to explain the observed associations. Similarly, while some end-of-life conditions can acutely lower total cholesterol, individuals who had these conditions or developed them were generally excluded from these trials’ analyses.

Conversely, there is support for the hypothesis that elevated LDL-C may have beneficial effects, particularly among the elderly. A growing body of research indicates LDL lipoproteins may support immune function (5). Multiple studies have indicated low LDL-C is associated with increased risk of infection-related hospitalization and death, which may be particularly relevant to elderly populations (6). Data has similarly indicated LDL-C is inversely associated with cancer risk and cancer mortality (7), a finding most dramatically illustrated by the low rates of cancer among individuals with familial hypercholesterolemia (8).

A closer look at clinical data further suggests LDL-C does not accurately predict cardiovascular risk. For example, LDL-C levels among patients hospitalized for a heart attack are often below the population average (9); patients who lower cholesterol further after a first heart attack have greater risk of heart attack recurrence and overall mortality than those who do not (10). These observations would seem to directly contradict the supposed causal role of LDL-C in atherosclerosis.

Taken together, this review indicates that if there is any association between LDL-C and mortality in the elderly, it is more likely to be an inverse association than a direct association. In light of these data and similar analyses conducted by members of this group (11), reassessment of major guidelines directing the treatment and management of heart disease, especially among the elderly, is warranted.

Read the review

Notes